| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Hybritech Incorporated, San Diego, California 92126
This communication describes the covalent modification of monoclonal and polyclonal antibodies with oxidized dextrans of low molecular weight to generate conjugates having low immunogenicity in vivo. Conjugation conditions were optimized to generate monomeric, dextran-modified antibodies, free of both high-molecular-weight polymeric aggregates and unmodified antibodies. Conjugates could be prepared with varying levels of dextran substitution. These conjugates retained optimal immunoreactivity as well as in vivo pharmacokinetics and tumor-localization properties. In addition, multiple i.v. administrations of dextran-modified antibodies in animals did not elicit a measurable immune response to either the antibody or the dextran portion of these conjugates.
1 To whom requests for reprints should be addressed, at Hybritech, Inc., P. O. Box 269006, San Diego, CA 92126.
Received 4/13/89.
Revised 2/22/90.
This article has been cited by other articles:
![]() |
D. L. Meyer, J. Schultz, Y. Lin, A. Henry, J. Sanderson, J. M. Jackson, S. Goshorn, A. R. Rees, and S. S. Graves Reduced antibody response to streptavidin through site-directed mutagenesis Protein Sci., March 1, 2001; 10(3): 491 - 503. [Abstract] [Full Text] |
||||
![]() |
D. Oupicky, K. Ulbrich, and B. Rihova Conjugates of Semitelechelic Poly[N-(2-Hydroxypropyl)Methacrylamide] with Enzymes for Protein Delivery Journal of Bioactive and Compatible Polymers, May 1, 1999; 14(3): 213 - 231. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |